Article: MethylGene Reports Third Quarter 2009 Financial Results.(Financial report)

MONTREAL, QUEBEC, Nov 5, 2009 (Marketwire via COMTEX) -- MethylGene Inc. (TSX:MYG) today announced financial results for the third quarter ended September 30, 2009.

Operational highlights of the quarter include:

- The U.S. Food and Drug Administration lifted the partial clinical hold for new patient enrollment previously placed on mocetinostat (MGCD0103), a histone deacetylase inhibitor for cancer. With the partial hold lifted, the Company expects to enroll new patients as soon as possible in its Phase II clinical trial in patients with relapsed or refractory follicular lymphoma (Trial 008).

- The Company initiated its Phase II program for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!